Skip to main content



Andrew Beelen currently serves as Executive Director of Clinical Development at G1 Therapeutics.  He has over 19 years of clinical drug development experience, primarily in the oncology therapeutic area.  Earlier in his career, he held increasing roles of responsibility including Vice President of Clinical Research at Myrexis (formerly Myriad Pharmaceuticals) and Director of Clinical Pharmacology and Discovery Medicine at GlaxoSmithKline, where he was responsible for the clinical pharmacology development program of lapatinib (TYKERB), including early phase combination chemotherapy studies.

Dr. Beelen earned his MD from SUNY Upstate Medical University in Syracuse, NY, and completed an internal medicine residency and clinical pharmacology fellowship at Dartmouth Hitchcock Medical Center in Lebanon, NH.  During his clinical pharmacology fellowship, Dr. Beelen was a sub-investigator for several Phase I oncology clinical trials.  He also holds a BS in Pharmacy from the Albany College of Pharmacy and Health Sciences in Albany, NY.